(Q46904227)

26 December 2017

title

Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine (English)

1 reference

26 December 2017

1

Shahin Lockman

1 reference

26 December 2017

author name string

James Alasdair McIntyre

series ordinal

2

1 reference

26 December 2017

language of work or name

English

0 references

publication date

7 November 2007

1 reference

26 December 2017

published in

The Lancet

1 reference

26 December 2017

volume

370

1 reference

26 December 2017

issue

9600

1 reference

26 December 2017

page(s)

1668-1670

1 reference

26 December 2017

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Site-specific interventions to improve prevention of mother-to-child transmission of human immunodeficiency virus programs in less developed settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group prot

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961606-7

7 January 2021

10.1016/S0140-6736(07)61606-7

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017